* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Nonselective beta-adrenergic blocking agent, carvedilol
Survey
Document related concepts
Coronary artery disease wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Hypertrophic cardiomyopathy wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Electrocardiography wikipedia , lookup
Heart failure wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Myocardial infarction wikipedia , lookup
Cardiac surgery wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Heart arrhythmia wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
Transcript
Journal of the American College of Cardiology © 2000 by the American College of Cardiology Published by Elsevier Science Inc. Vol. 36, No. 5, 2000 ISSN 0735-1097/00/$20.00 PII S0735-1097(00)00900-1 Nonselective Beta-Adrenergic Blocking Agent, Carvedilol, Improves Arterial Baroflex Gain and Heart Rate Variability in Patients With Stable Chronic Heart Failure Andrea Mortara, MD, Maria Teresa La Rovere, MD, Gian Domenico Pinna, BE, Roberto Maestri, BE, MD, Soccorso Capomolla, MD, Franco Cobelli, MD Pavia, Italy The purpose of this study was to investigate in a case-controlled study whether carvedilol increased baroreflex sensitivity and heart rate variability (HRV). BACKGROUND In chronic heart failure (CHF), beta-adrenergic blockade improves symptoms and ventricular function and may favorably affect prognosis. Although beta-blockade therapy is supposed to decrease myocardial adrenergic activity, data on restoration of autonomic balance to the heart and, particularly, on vagal reflexes are limited. METHODS Nineteen consecutive patients with moderate, stable CHF (age 54 ⫾ 7 years, New York Heart Association [NYHA] class II to III, left ventricular ejection fraction [LVEF] 24 ⫾ 6%), treated with optimized conventional medical therapy, received carvedilol treatment. Controls with CHF were selected from our database on the basis of the following matching criteria: age ⫾ 3 years, same NYHA class, LVEF ⫾ 3%, pulmonary wedge pressure ⫾ 3 mm Hg, peak volume of oxygen ⫾ 3 ml/kg/min, same therapy. All patients underwent analysis of baroreflex sensitivity (phenylephrine method) and of HRV (24-h Holter recording) at baseline and after six months. RESULTS Beta-blockade therapy was associated with a significant improvement in symptoms (NYHA class 2.1 ⫾ 0.4 vs. 1.8 ⫾ 0.5, p ⬍ 0.01), systolic and diastolic function (LVEF 23 ⫾ 7 vs. 28 ⫾ 9%, p ⬍ 0.01; pulmonary wedge pressure 17 ⫾ 8 vs. 14 ⫾ 7 mm Hg, p ⬍ 0.05) and mitral regurgitation area (7.0 ⫾ 5.1 vs. 3.6 ⫾ 3.0 cm2, p ⬍ 0.01). No significant differences were observed in either clinical or hemodynamic indexes in control patients. Phenylephrine method increased significantly after carvedilol (from 3.7 ⫾ 3.4 to 7.1 ⫾ 4.9 ms/mm Hg, p ⬍ 0.01) as well as RR interval (from 791 ⫾ 113 to 894 ⫾ 110 ms, p ⬍ 0.001), 24-h standard deviation of normal RR interval and root mean square of successive differences (from 56 ⫾ 17 to 80 ⫾ 28 ms and from 12 ⫾ 7 to 18 ⫾ 9 ms, all p ⬍ 0.05), while all parameters remained unmodified in controls. During a mean follow-up of 19 ⫾ 8 months a reduced number of cardiac events (death plus heart transplantation, 58% vs. 31%) occurred in those patients receiving beta-blockade. CONCLUSIONS Besides the well-known effects on ventricular function, treatment with carvedilol in CHF restores both autonomic balance and the ability to increase reflex vagal activity. This protective mechanism may contribute to the beneficial effect of beta-blockade treatment on prognosis in CHF. (J Am Coll Cardiol 2000;36:1612– 8) © 2000 by the American College of Cardiology OBJECTIVES In controlled clinical trials, long-term treatment of patients with chronic heart failure (CHF) with the third generation nonselective beta-adrenergic blocking agent, carvedilol, improves symptoms, slows progression of the disease and may reduce morbidity and mortality (1–3). Several mechanisms may contribute to the beneficial effect of carvedilol (4), including a direct effect on beta-adrenoreceptors with inhibition of sympathetic overactivity. Since neurohormonal activation has been reported to be one of the major causes in the progression of heart failure and ventricular dysfunction, its restraint by beta-blockers might be an important tool in the treatment of CHF. From the Department of Cardiology, Centro Medico di Montescano, “S. Maugeri” Foundation, IRCCS, Pavia, Italy. Supported directly by “S. Maugeri” Foundation, IRCCS, Pavia, Italy. Manuscript received July 29, 1999; revised manuscript received April 10, 2000, accepted June 15, 2000. Autonomic nervous system integrity may be quantified noninvasively in the clinical setting by analysis of heart rate variability (HRV) and arterial baroreceptor function (5–7). It has been shown that the two measures, although related to sympathovagal activity, reflect different physiological mechanisms. While HRV is considered a marker of tonic sympathetic and vagal outflow, baroreflex sensitivity (BRS) represents the capability of the cardiovascular regulatory system to increase vagal activity by reflex. Both parameters are depressed in CHF (5,8,9) and may identify patients at higher risk of cardiac death and unfavorable outcome (10,11). Beta-blockers have been shown to modulate HRV and vagal reflexes in normal subjects, hypertensive and postmyocardial infarction patients (12–22), but sparse and inconsistent data have been reported for patients with CHF (23–25). The aim of our study was to demonstrate in a case-controlled study whether treatment with the nonselec- JACC Vol. 36, No. 5, 2000 November 1, 2000:1612–8 Abbreviations and Acronyms ANOVA ⫽ analysis of variance BRS ⫽ baroreflex sensitivity CHF ⫽ chronic heart failure HRV ⫽ heart rate variability LVEF ⫽ left ventricular ejection fraction NYHA ⫽ New York Heart Association rMSSD ⫽ root mean square of successive differences SAP ⫽ systolic arterial pressure SDNN ⫽ 24-h standard deviation of normal RR interval tive beta-blocker, carvedilol, improves vagal reflexes to the heart and reduces sympathetic overactivity as evaluated by assessment of arterial baroreceptor function and HRV analysis. METHODS Study protocol and population. A case-controlled study was a predefined choice to minimize in a limited number of patients any possible differences in the level of ventricular dysfunction between treated and nontreated patients. Twenty consecutive subjects with moderate to severe CHF in a clinical stable phase and optimized conventional medical treatment with angiotensin-converting enzyme inhibitors, digoxin and diuretics underwent a one-month betablocker titration period with carvedilol. Dosage of the drug started from 3.25 mg twice daily and was progressively increased until the maximum tolerated dose (max 25 mg twice a day). During this time other drug therapies were kept constant with the exception of diuretics, which were adjusted according to the appearance of signs of fluid retention. Twenty patients selected from those enrolled in the heart failure database of Montescano Medical Center (n ⫽ 640) were retrospectively matched with the patients treated with beta-blockers. The following clinical and hemodynamic baseline matching criteria were used: age ⫾ 3 years, same etiology, same New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF) ⫾ 3%, pulmonary wedge pressure ⫾ 3 mm Hg, max volume of oxygen exercise capacity ⫾ 3 ml/kg/min. Patients who were treated with amiodarone and beta-blockers were excluded from the matching analysis. None had a history of pulmonary or neurological disease or an acute myocardial infarction and cardiac surgery within the previous six months. In order to be entered into the database, all CHF patients had to have been in a stable condition with no changes in signs or symptoms in the two weeks preceding the study. At the first assessment and at the end of follow-up, all patients underwent echocardiography with Doppler ultrasound examination, right heart catheterization, cardiopulmonary exercise test, 24-h Holter recording with HRV analysis and BRS assessment. All patients gave informed consent for the Mortara et al. Effect of Carvedilol on Autonomic Nervous System in CHF 1613 study, and the study was approved by the local ethical committee. Baroreflex sensitivity assessment. Arterial baroreceptor function was evaluated by administration of the vasoactive drug, phenylephrine, according to the well-established method proposed by Smyth et al. (26). Baroreflex sensitivity studies were analyzed by two independent and experienced observers (A.M. and M.T.L.R.), as previously described (7,11). Briefly, one electrocardiogram lead and systolic arterial pressure obtained noninvasively via a photoplethysmographic transducer (Finapres, Ohmeda) were continuously recorded. Phenylephrine HCl (starting dosage 3 to 4 g/kg) was given to raise the systolic arterial pressure (SAP) by 15 to 30 mm Hg. The RR intervals were plotted against the preceding arterial systolic peak, and a linear regression analysis was performed for those points included between the beginning and the end of the first significant increase in SAP. Regression lines with a statistically significant correlation coefficient (p ⬍ 0.05) were accepted for analysis; only for BRS near to zero (⫾ 0.5 ms/mm Hg), if the increase of SAP was adequate (above 15 mm Hg), the coefficients of regression were accepted independent of the p value. This approach is justified by the fact that if SAP increase causes no reflex changes (or small erratic changes) of RR interval, the correlation between delta values of SAP and RR would be necessarily poor with a regression line running along the horizontal axis. A final slope was obtained by calculating the mean value of the injections performed at the optimal phenylephrine dose. This value was then considered as representing BRS (ms of RR change/1 mm Hg of SAP increase). Ambulatory electrocardiogram monitoring. Patients underwent 24-h Holter monitoring using a three-channel Oxford recorder (Oxford Medical Instruments, United Kingdom). All tapes were analyzed using the Oxford Excell II Holter system for QRS labeling and arrhythmia detection. The tapes were manually reviewed by an independent observer who was blind to the patient’s identity and study treatment. Measurements of HRV were: standard deviation of normal RR interval (SDNN) and root mean square of successive differences (rMSSD). These time-domain parameters were chosen because they appear to be stable and reproducible not only in normal subjects but also in various subsets of patients with cardiovascular diseases, including CHF failure (27). Hemodynamic and Doppler echocardiographic evaluation. Right-sided heart catheterization was performed using a 7F Swan-Gantz balloon-tipped catheter inserted into the right internal jugular vein and advanced through the right heart into the pulmonary artery. Baseline standard hemodynamic measurements, including pulmonary artery pressure, mean pulmonary artery wedge pressure and mean right atrial pressure, were made with the patients in a supine position using a Hewlett Packard transducer (Andover, Massachusetts) connected with a 7005 Marquette polygraph (Marquette Electronic, Milwaukee, Wisconsin) and re- 1614 Mortara et al. Effect of Carvedilol on Autonomic Nervous System in CHF corded at a speed of 50 mm/s on a scale calibrated from 0 to 50 mm Hg. Cardiac output was measured by the thermodilution method as the mean of three consecutive measurements not varying by more than 10%. A Hewlett Packard 1000 ultrasound system with 2.5 and 3.5 MHz probes was used to perform Doppler and twodimensional echocardiographic examinations, which were obtained with the patients lying in a supine or slightly left lateral decubitus position. Examinations were recorded on a super-VHS videotape and analyzed by an experienced cardiologist. Left ventricular volumes and left ventricular ejection fraction (LVEF) were assessed by two-dimensional apical 2- and 4-chamber views using the modified Simpson’s rule. Mitral regurgitation was diagnosed and semiquantitatively graded by color-flow Doppler from the apical view. Statistical methods. Comparisons between groups at baseline were performed by analysis of variance (ANOVA) for continuous variables and by the chi-square test for categorical variables, whereas analyses before and after treatment were performed by two-way ANOVA for repeated measures. Regression analysis was employed to assess the relation between changes in LVEF and autonomic nervous system parameters. Because of the skewed distribution of BRS, Wilcoxon’s signed-rank test, Kruskal-Wallis ANOVA and Spearman’s rank correlation procedure were used when appropriate. All the analyses were performed using the STATISTICA/W statistical package (Tulsa, Oklahoma). Differences were considered significant when a p value of ⬍ 0.05 was observed. All results are reported as mean ⫾ SD. RESULTS Nineteen patients tolerated treatment with beta-blockers, and the mean dosage at the end of follow-up was 40 ⫾ 18 mg/day. One subject experienced worsening of heart failure that required extensive modification of the treatment and was excluded from the analysis. Clinical and hemodynamic characteristics and autonomic nervous system parameters of the final 19 treated patients and of the 19 controls at baseline are reported in Tables 1 and 2. The two groups were almost identical in terms of level of ventricular dysfunction, and no significant differences were present in either HRV or BRS. Figure 1 shows the changes of matching variables in treated and control patients. Beta-blockade therapy was associated with a significant improvement in symptoms and signs of ventricular impairment, while no differences were observed in control subjects. Moreover, carvedilol caused a significant reduction of the mitral regurgitation area (Fig. 1). The effect of treatment on autonomic parameters is shown in Table 2. After beta-blockade, the RR interval lengthened significantly, and both BRS and HRV indexes showed a marked improvement. In contrast, all autonomic nervous system parameters remained unmodified in control JACC Vol. 36, No. 5, 2000 November 1, 2000:1612–8 Table 1. Baseline Clinical and Hemodynamic Characteristics in Controls and in Patients Treated With Beta-blockers Matching criteria Age (yrs) Etiology (%) Ischemic Idiopathic Valvular NYHA (class) LVEF (%) CI (L/min/m2) PWP (mm Hg) VO2 max (ml/kg/min) Not matching Criteria Duration of symptoms (months) Na⫹ (mEq/L) Echo deceleration time (s) Mitral regurgitation 3–4⫹ (%) RAP (mm Hg) Therapy ACE-inhibitors (%) Diuretics (%) Nitrates (%) Digoxin (%) Other vasodilators (%) Controls (n ⴝ 19) Beta blockade (n ⴝ 19) 53 ⫾ 8 53 ⫾ 8 47.5 47.5 5 2.1 ⫾ 0.4 23.6 ⫾ 5.8 2.3 ⫾ 0.5 17.7 ⫾ 8.9 14.8 ⫾ 4.0 47.5 47.5 5 2.1 ⫾ 0.4 23.8 ⫾ 7.3 2.4 ⫾ 0.5 17.4 ⫾ 8.4 14.5 ⫾ 3.8 25 ⫾ 18 138 ⫾ 4 121 ⫾ 30 53 5.8 ⫾ 4 24 ⫾ 11 138 ⫾ 3 127 ⫾ 37 47.5 3.9 ⫾ 3 89 94 57 89 5 94 94 63 84 5 ACE ⫽ angiotensin-converting enzyme; CI ⫽ cardiac index; LVEF ⫽ left ventricular ejection fraction; Na⫹ ⫽ serum sodium concentration; NYHA ⫽ New York Heart Association functional class; PWP ⫽ mean pulmonary wedge pressure; RAP ⫽ mean right atrial pressure; VO2 max ⫽ maximum O2 consumption during exercise. Values are mean ⫾ SD. subjects. Individual data on BRS and SDNN changes after beta-blockade are displayed in Figure 2; the mean delta increase was 3.8 ⫾ 4 ms/mm Hg and 24 ⫾ 16 ms, respectively. In treated patients there was a significant relation between the delta changes in BRS and SDNN (r ⫽ 0.59, p ⬍ 0.01), while neither measure was related to the changes in mean 24-h RR interval (r ⫽ 0.16 for BRS and r ⫽ 0.32 for SDNN, both NS). In addition, a significant association was found between delta changes in LVEF and delta changes in BRS or SDNN (Fig. 3). During a subsequent period of follow-up of 19 ⫾ 8 months, five patients underwent cardiac transplantation, and six cardiac deaths occurred in the control group, while three cardiac deaths and three cardiac transplantations were registered in those patients treated with carvedilol, thus confirming a reduced prevalence of total cardiac events (from 58% to 31%). DISCUSSION This case-controlled study clearly demonstrates that in mild to severe stable patients with CHF with optimized medical treatment, additional therapy with the nonselective betablocker, carvedilol, improves baseline vagal activity and the baroreflex control of heart rate. This finding has clinically relevant implications since in these patients the restoration of more physiological dynamics of baroreceptor reflexes and Mortara et al. Effect of Carvedilol on Autonomic Nervous System in CHF JACC Vol. 36, No. 5, 2000 November 1, 2000:1612–8 1615 Table 2. Autonomic Nervous System Parameters at Baseline and at the End of Follow-up in Controls and in Patients Treated With Beta-blockers Controls (n ⴝ 19) Baroreflex sensitivity BRS slope (ms/mm Hg) Baseline SBP (mm Hg) Baseline RR interval (ms) Delta SBP increase (mm Hg) Delta RR interval increase (ms) Heart rate variability RR interval (ms) SDNN (ms) rMSSD (ms) Beta-blockade (n ⴝ 19) Baseline 6-month Baseline 6-month 4.0 ⫾ 3.7 109 ⫾ 15 848 ⫾ 157 18.8 ⫾ 5.1 95 ⫾ 66 4.2 ⫾ 3.1 110 ⫾ 14 852 ⫾ 145 18.5 ⫾ 4.0 94 ⫾ 64 3.7 ⫾ 3.4 108 ⫾ 11 802 ⫾ 128 18.1 ⫾ 5.0 88 ⫾ 83 7.1 ⫾ 4.9*† 114 ⫾ 8*† 981 ⫾ 131*† 19.4 ⫾ 5.9 210 ⫾ 170*† 807 ⫾ 121 57 ⫾ 16 15 ⫾ 9 782 ⫾ 117 61 ⫾ 13 14 ⫾ 12 791 ⫾ 113 56 ⫾ 17 12 ⫾ 7 894 ⫾ 110*† 80 ⫾ 28*† 18 ⫾ 9* BRS ⫽ baroreflex sensitivity; rMSSD ⫽ root mean square of successive differences, SBP ⫽ systolic blood pressure; SDNN ⫽ standard deviation of 24-h normal RR interval. *denotes p ⬍ 0.05 vs. baseline; †denotes p ⬍ 0.05 vs. controls at 6 months. a more favorable sympathovagal balance to the heart may protect against arrhythmogenic mechanisms and contribute to a better outcome. After an observation period of six months, hemodynamic and autonomic measures remained stable in control patients thus confirming that the beneficial improvement in functional and autonomic indexes observed in treated patients was related only to the additive effect of carvedilol. Carvedilol in heart failure. Recent meta-analyses focused on the results of randomized trials with beta-blockers in CHF (1–3) have emphasized that carvedilol is highly effective in reducing symptoms of heart failure, limiting hospitalization and increasing survival. Moreover, carvedilol improves LVEF and positively affects ventricular remodel- ing by reducing left ventricular volumes and preventing progressive ventricular dilation (4). In accordance with these data, we observed a significant improvement of both systolic and diastolic functions with a marked reduction of mitral regurgitation. Since only stable CHF patients were enrolled in this study, carvedilol was well tolerated and only in one subject was treatment interrupted due to the worsening of heart failure. The mechanisms involved in the positive effect of carvedilol, particularly on systolic function, are still uncertain. One proposal is that heart rate slowing with a beneficial effect on diastolic times may be involved, as might be a direct protective action on the myocytes against cathecolamine excess. Moreover, a combined effect of carvedilol at different sites through adrenoreceptor blockade Figure 1. Bar graph showing changes at six months of clinical and hemodynamic parameters in controls and in patients treated with beta-blockers. A significant improvement of all indexes is shown after beta-blockade, while they remain unmodified in controls. LVEF ⫽ left ventricular ejection fraction; NYHA ⫽ New York Heart Association. 1616 Mortara et al. Effect of Carvedilol on Autonomic Nervous System in CHF JACC Vol. 36, No. 5, 2000 November 1, 2000:1612–8 Figure 2. Individual changes of BRS (upper panels) and SDNN (lower panels) at six months in controls and in patients treated with carvedilol. BRS ⫽ baroreflex sensitivity; SDNN ⫽ 24-h standard deviation of normal RR interval. and reduction of norepinephrine content (28,29) may cause a significant increase in the sarcoplasmic Ca2⫹ content of ventricular myocytes with a consequent improvement in contractile performance (30). We found a significant correlation between changes in LVEF and autonomic nervous system parameters (Fig. 3). Although the causality of this association could not be established in the context of this study, this relation does confirm a parallel improvement of neural and hemodynamic indexes. In this limited subset of patients, it is confirmed that beta-blockade treatment is associated with a reduced number of cardiac events in CHF (mortality was double in control patients). It is suggested that, among the mechanisms involved in this beneficial effect of carvedilol, a restorative change of the autonomic function is likely to play a significant role. Effects of carvedilol on HRV and baroreflex sensitivity. The effect of beta-blockade therapy on autonomic measures has been extensively analyzed in healthy subjects and in patients with hypertension or recent myocardial infarction (12–22) but only few data have been reported in CHF (23–25). It is generally accepted that beta-blocker treatment increases mean RR interval and all HRV measures strictly related to vagal activity. In CHF all parameters of HRV are markedly reduced, and this has been interpreted as being the result of a shift of autonomic balance towards a sympathetic predominance (5). The mechanisms and clinical implications of reduced HRV in CHF and the occurrence of possible confounding factors in the analysis of HRV have been recently reviewed (5,8). Indeed, it has been reported that SDNN during 24-h recording probably reflects the sum of multiple neural and nonneural effects on the sinus node, which also include chemoreceptor influences, fluctuations in tidal volumes and other slow neurohormonal modulators of cardiac rhythm (8). In this context, the UK-Heart prospective study (10) has recently demonstrated in more than 400 outpatients with mild to moderate heart failure that reduced SDNN was the best noninvasive independent predictor of cardiac death. In this study, carvedilol significantly improved SDNN, and this was not accounted for by the increase in RR interval. This finding confirms that betablocker treatment exerts a positive effect on the mechanisms that sustain the harmful hyperadrenergic state and affect prognosis. As far as arterial baroreflex gain is concerned, it has been known since 1970 that beta-blockers can improve the reflex response of heart rate to both blood pressure increase (31) and the direct stimulation of baroreceptors by neck suction (32). In normal subjects (18 –20) and in a limited number of patients with hypertension (20,21), it was shown that JACC Vol. 36, No. 5, 2000 November 1, 2000:1612–8 Figure 3. Scatterplots illustrating the relation between changes in LVEF and changes in BRS (top panel) or SDNN (bottom panel) after betablockade. A significant relation between LVEF and both autonomic indexes is shown. BRS ⫽ baroreflex sensitivity; LVEF ⫽ left ventricular ejection fraction; SDNN ⫽ 24-h standard deviation of normal RR interval. beta-blockers significantly increase baroreflex gain and that this effect is independent of the beta-blocker used. We previously demonstrated (11) in a large group of patients with stable chronic heart failure that: 1) BRS as measured by the phenylephrine technique is markedly depressed in CHF, 2) the relation of BRS with all indexes of ventricular function, although significant, is fairly weak, and 3) BRS quantification adds prognostic information to the predictive accuracy of other established risk factors such as age, LVEF and maximum oxygen consumption during exercise (11). The mechanism of this arterial baroreflex dysfunction in CHF has been described in detail elsewhere (9,11,33,34). It is probably multifactorial, may be located in all components of the reflex arc and includes central and peripheral effects of high levels of angiotensin II. In this study, we observed a marked improvement of BRS after carvedilol treatment, and this was fully dependent on enhancement of the RR reflex response since the blood pressure increase induced by phenylephrine (the stimulus evoking the reflex) was identical at baseline and after therapy. Different possible explanations may be considered for the effectiveness of carvedilol on baroreflex control of heart rate, and these include hemodynamic mediated effects and direct effects related to beta-receptor blockade. Arterial Mortara et al. Effect of Carvedilol on Autonomic Nervous System in CHF 1617 baroreceptors are sensitive to carotid distending pressure, and their firing increases in response to small increments of pressure (6,9). In this study, carvedilol significantly improved LVEF and reduced mitral regurgitation thus causing an increase in both the absolute value and slope of the stroke volume. This is confirmed by the study of Metra et al. (35) who found that four months of carvedilol therapy produced a significant increase in resting and exercise stroke volume and stroke volume index. It is unquestionable that such profound changes of systolic function and, consequently, in carotid pressure could be responsible, at least in part, for the restoration of baroreflex function. Moreover, because the bradycardia that occurs in response to the hypertensive stimulus is mediated largely by an increase in parasympathetic tone and is affected by adrenergic hyperactivity, any changes in sympathetic and vagal efferent outflow to the sinus node that resulted from modulation of other reflexogenic areas by beta-blockade treatment would interfere with the assessment of BRS. Our data are in agreement with a previous report that has clearly demonstrated that carvedilol lowered other indexes of cardiac adrenergic activity, namely coronary sinus and transmyocardial norepinephrine levels (29). Theoretically, variations in SDNN and BRS could be dependent on the same mechanisms influenced by carvedilol therapy. However, the significant correlation we observed between changes of the two measures may support either a noncausal or a causal relationship, indicating a possible direct effect of baroreflex improvement on HRV indexes. Indeed, it has been demonstrated that arterial baroreceptors are important modulators of respiratory and nonrespiratory fluctuations of heart rate (5,36,37). As a consequence, it would not be surprising if changes in BRS were found to affect changes in HRV. Study limitations. A possible limitation of our study is the small sample size and the retrospective comparison with a control group. However, because noninvasive evaluation of autonomic nervous system analysis in CHF can be markedly dependent on the level of hemodynamic dysfunction and because possible differences in baseline clinical characteristics can persist in a limited number of randomized patients, a case-controlled study was preferred to a randomized one. Patients were consecutively allocated to the treatment arm, and the controls were obtained after specific matching for the most important clinical and hemodynamic variables. This allowed us to have two identical groups at baseline, such that any changes in ventricular function or autonomic parameters could be ascribed only to the carvedilol treatment. Spectral parameters (low- and high-frequency components, low-frequency/high-frequency ratio) were deliberately not used for the purposes of the present study since: 1) recordings were not performed under resting controlled conditions, and 2) it is well known that in CHF, lowfrequency and high-frequency powers are of limited value for assessing autonomic modulation of heart rate (38 – 40). In conclusion, this study shows that therapy with the Mortara et al. Effect of Carvedilol on Autonomic Nervous System in CHF JACC Vol. 36, No. 5, 2000 November 1, 2000:1612–8 nonselective beta-blocker, carvedilol, significantly modifies arterial baroreflex control of heart rate and the sympatheticparasympathetic interaction to the heart. This positive effect on autonomic nervous system parameters is accompanied by favorable changes in systolic and diastolic dysfunction and suggests that carvedilol in CHF patients has the potential to produce greater cardioprotection from harmful adrenergic overactivity. variability after first acute myocardial infarction. Am J Cardiol 1998; 81:834 – 40. Pitzalis MV, Mastropasqua F, Massari F, et al. Beta-blocker effects on respiratory sinus arrhythmia and baroreflex gain in normal subjects. Chest 1998;114:185–91. Floras JS, Jones JV, Hassan MO, Sleight P. Effects of acute and chronic beta-adrenoceptor blockade on baroreflex sensitivity in humans. J Auton Nerv Syst 1988;25: 87–94. Lucini D, Pagani M, Mela GS, Malliani A. Sympathetic restraint of baroreflex control of heart period in normotensive and hypertensive subjects. Clin Sci 1994;86:547–56. Parati G, Mutti E, Frattola A, Castiglioni P, di Roenzo M, Mancia G. Beta-adrenergic blocking treatment and 24-h baroreflex sensitivity in essential hypertensive patients. Hypertension 1994;23:992– 6. Airaksinen KEJ, Niemela MJ, Huikuri HV. Effect of beta-blockade on baroreflex sensitivity and cardiovascular autonomic function tests in patients with coronary disease. Eur Heart J 1994;15:1482–5. Pousset F, Copie X, Lechat P, et al. Effects of bisoprolol on heart rate variability in heart failure. Am J Cardiol 1996;77:612–7. Goldsmith RL, Bigger JT, Bloomfield DM, et al. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol 1997;80:1101– 4. Sanderson JE, Yeung LY, Chan S, et al. Effect of beta-blockade on baroreceptor and autonomic function in heart failure. Clin Sci 1999; 96:137– 46. Smyth HS, Sleight P, Pickering GW. Reflex regulation of arterial pressure during sleep in man: a quantitative method for assessing baroreflex sensitivity. Circ Res 1969;24:109 –21. Van Hoogenhuyze D, Weinstein N, Martin GJ, et al. Reproducibility and relation to mean heart rate of heart rate variability in normal subjects and in patients with congestive heart failure secondary to coronary disease. Am J Cardiol 1991;68:1668 –76. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17 Suppl B:8 –16. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular function and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817–25. Erdmann E. Pathophysiology of heart failure. Heart 1998;79 Suppl 2:S3–S5. Pickering TG, Gribbin B, Petersen ES, Cunningham DJC, Sleight P. Effects of autonomic blockade on the baroreflexes in man at rest and during exercise. Circ Res 1972;30:175– 85. Eckberg DL, Abboud FM, Mark AL. Modulation of carotid baroreflex responsiveness in man: effects of posture and propanolol. J Appl Physiol 1976;41:383–7. Sopher SM, Smith ML, Eckberg DL, Fritsch JM, Dibner-Dunlap ME. Autonomic pathophysiology in heart failure: carotid baroreceptor-cardiac reflexes. Am J Physiol 1990;259:H689 –96. Thames MD, Kinugawa T, Smith ML, Dibner-Dunlap ME. Abnormalities of baroreflex control in heart failure. J Am Coll Cardiol 1993;22A:56A– 60A. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678 – 87. Piepoli M, Sleight P, Leuzzi S, et al. Origin of respiratory sinus arrhythmias in conscious humans. An important role for arterial carotid baroreceptors. Circulation 1997;95:1813–21. Sleight P, La Rovere MT, Mortara A, et al. Physiology and pathophysiology of heart rate and blood pressure variability in humans: is power spectral analysis largely an index of baroreflex gain? Clin Sci 1995;88:103–9. Casadei B, Moon J, Johnston J, Caiazza A, Sleight P. Is respiratory sinus arrhythmia a good index of cardiac vagal tone in exercise? Am J Physiol 1996;81:556 – 64. Mortara A, La Rovere MT, Signorini MG, et al. Can power spectral analysis of heart rate variability identify a high risk subgroup of congestive heart failure patients with excessive sympathetic activation? A pilot study before and after heart transplantation. Br Heart J 1994;71:422–30. van de Born P, Montano N, Pagani M, Oren R, Somers VK. Absence of low-frequency variability of sympathetic nerve activity in severe heart failure. Circulation 1997;95:1449 –54. 1618 18. 19. 20. 21. Reprint requests and correspondence: Dr. Andrea Mortara, Division of Cardiology, Centro Medico di Montescano, “S. Maugeri” Foundation, IRCCS, Montescano, Pavia, Italy. E-mail: [email protected]. 22. 23. REFERENCES 1. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boisset JP. Clinical effects of beta-adrenergic blockade in chronic heart failure. A meta-analysis of double blind, placebo-controlled, randomized trials. Circulation 1998;98:1184 –91. 2. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27–34. 3. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomized controlled trials. Eur Heart J 1997;18:560 –5. 4. Frishman WH. Carvedilol. N Engl J Med 1998;339:1759 – 65. 5. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043– 65. 6. Mancia G, Mark AL. Arterial baroreflexes in humans. In: Shepherd JT, Abboud FM, editors. Handbook of Physiology. Section 3: The Cardiovascular System. Bethesda: American Physiological Society, 1983:755–94. 7. La Rovere MT, Mortara A, Schwartz PJ. Baroreflex sensitivity. J Cardiovasc Electrophysiol 1995;6:761–74. 8. Lombardi F, Mortara A. Heart rate variability and cardiac failure. Heart 1998;80:213– 4. 9. Eckberg DL, Sleight P. Congestive heart failure. In: Eckberg DL, Sleight P, editors. Human Baroreflexes in Health and Disease. Oxford: Clarendon Press, 1992:399 – 436. 10. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure. Results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart). Circulation 1998;98:1510 – 6. 11. Mortara A, La Rovere MT, Pinna GD, et al. Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation 1997;96: 3450 – 8. 12. Cook JR, Bigger JT, Jr., Kleiger RE, Fleiss JL, Steinman RC, Rolnitzky LM. Effect of atenolol and diltiazem on heart period variability in normal persons. J Am Coll Cardiol 1991;17:480 – 4. 13. Niemela MJ, Airaksinen KEJ, Huikuri HV. Effect of beta-blockade on heart rate variability in patients with coronary artery disease. J Am Coll Cardiol 1994;23:1370 –7. 14. Sandrone G, Mortara A, Torzillo D, La Rovere MT, Malliani A, Lombardi F. Effects of beta-blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am J Cardiol 1994; 74:340 –5. 15. Tuninga YS, Crijns HJCM, Brouwer J, et al. Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients. Circulation 1995;92:3415–23. 16. Keeley EC, Page RL, Lange RA, Willard JE, Landau C, Hillis LD. Influence of metoprolol on heart rate variability in survivors of remote myocardial infarction. Am J Cardiol 1996;77:557– 60. 17. Malfatto G, Facchini M, Sala L, Branzi G, Bragato R, Leonetti G. Effects of cardiac rehabilitation and beta-blocker therapy on heart rate 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40.